Dietary fibers as immunoregulatory compounds in health and disease

Annals of the New York Academy of Sciences

Volumn 1190, Issue , 2010, Pages 70-85

  Wismar, René ^a   Brix, Susanne ^a   Frøkiær, Hanne ^b   Lærke, Helle Nygaard ^c  

^a TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

Bioavailability; C type lectin receptor; Dendritic cells; Immune modulation; Mannan; Nonstarch polysaccharides; Glucan

Indexed keywords

BETA GLUCAN; CARBOHYDRATE BINDING RECEPTOR; CELL PROTEIN; IMMUNOMODULATING AGENT; IODINE 125; IODINE 125 PHYCARINE; NONSTARCH POLYSACCHARIDE; NONSTEROID ANTIINFLAMMATORY AGENT; POLYSACCHARIDE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; BLOATING; CARBOHYDRATE ANALYSIS; CONFERENCE PAPER; DENDRITIC CELL; DIETARY FIBER; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG FATALITY; FLATULENCE; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOSTIMULATION; IN VIVO STUDY; LIQUID FECES; MACROPHAGE; MOLECULAR WEIGHT; NONHUMAN; PEYER PATCH; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION;

EID: 77950248238     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05256.x     Document Type: Conference Paper

References (105)

1. McIntosh,M., B.A. Stone & V.A. Stanisich. 2005. Curdlan and other bacterial (1→3)-beta-D-glucans. Appl. Microbiol. Biotechnol. 68: 163-173.
2. Taylor, M.E. & K. Drickamer. 2007. Paradigms for glycan-binding receptors in cell adhesion. Curr. Opin. Cell Biol. 19: 572-577.
3. Appelmelk, B.J. et al. 2003. Cutting edge: carbohydrate profiling identifies new pathogens that interact with dendritic cell-specific ICAM-3-grabbing nonintegrin on dendritic cells. J. Immunol. 170: 1635-1639.
4. Blixt, O. et al. 2004. Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. Proc. Natl. Acad. Sci. USA 101: 17033-17038.
5. Largent, B.L. et al. 1984. Carbohydrate-specific adhesion of alveolar macrophages to mannose-derivatized surfaces. J. Biol. Chem. 259: 1764-1769.
6. Brown, G.D. 2006. Dectin-1: a signalling non-TLR pattern-recognition receptor. Nat. Rev. Immunol 6: 33-43.
7. Adams, E.L. et al. 2008. Differential high-affinity interaction of dectin-1 with natural or synthetic glucans is dependent upon primary structure and is influenced by polymer chain length and side-chain branching. J. Pharmacol. Exp. Ther. 325: 115-123.
8. Palma, A.S. et al. 2006. Ligands for the beta-glucan receptor, Dectin-1, assigned using "designer" microarrays of oligosaccharide probes (neoglycolipids) generated from glucan polysaccharides. J. Biol. Chem. 281: 5771-5779.
9. Ross, G.D. 2000. Regulation of the adhesion versus cytotoxic functions of the Mac-1/CR3/alphaMbeta2- integrin glycoprotein. Crit. Rev. Immunol. 20: 197-222.
10. Thornton, B.P. et al. 1996. Analysis of the sugar specificity and molecular location of the betaglucan- binding lectin site of complement receptor type 3 (CD11b/CD18). J. Immunol. 156: 1235-1246.
11. McGreal, E.P. et al. 2006. The carbohydrate-recognition domain of Dectin-2 is a C-type lectin with specificity for high mannose. Glycobiology 16: 422-430.
12. Bates, E.E. et al. 1999. APCs express DCIR, a novel Ctype lectin surface receptor containing an immunoreceptor tyrosine-based inhibitory motif. J. Immunol 163: 1973-1983.
13. Wells, C.A. et al. 2008. The macrophage-inducible Ctype lectin, mincle, is an essential component of the innate immune response to Candida albicans. J. Immunol. 180: 7404-7413.
14. Liew, F.Y. et al. 2005. Negative regulation of toll-like receptor-mediated immune responses. Nat. Rev. Immunol. 5: 446-458.
15. O'Neill, L.A. 2008. When signaling pathways collide: positive and negative regulation of toll-like receptor signal transduction. Immunity 29: 12-20.
16. Chieppa, M. et al. 2003. Cross-linking of the mannose receptor on monocyte-derived dendritic cells activates an anti-inflammatory immunosuppressive program. J. Immunol. 171: 4552-4560.
17. Geijtenbeek, T.B. et al. 2003. Mycobacteria target DCSIGN to suppress dendritic cell function. J. Exp. Med. 197: 7-17.
18. van Kooyk, Y. & G.A. Rabinovich. 2008. Protein-glycan interactions in the control of innate and adaptive immune responses. Nat. Immunol. 9: 593-601.
19. Takeda, K., T. Kaisho & S. Akira. 2003. Toll-like receptors. Annu. Rev. Immunol. 21: 335-376.
20. Kaisho, T. & T. Tanaka. 2008. Turning NF-kappaB and IRFs on and off in DC. Trends Immunol. 29: 329-336.
21. Sandula, J., E.Machova& V.Hribalova. 1995.Mitogenic activity of particulate yeast beta-(1→3)-D-glucan and its water-soluble derivatives. Int. J. Biol. Macromol. 17: 323-326.
22. Sandula, J. et al. 1999. Microbial (1 → 3)-beta-Dglucans, their preparation, physico-chemical characterization and immunomodulatory activity. Carbohyd. Polym. 38: 247-253.
23. Zekovic, D.B. et al. 2005. Natural and modified (1 → 3)-beta-D-glucans in health promotion and disease alleviation. Crit. Rev. Biotechol. 25: 205-230.
24. Xiao, Z., C.A. Trincado & M. P. Murtaugh. 2004. Betaglucan enhancement of T cell IFNgamma response in swine. Vet. Immunol Immunopathol. 102: 315-320.
25. Novak, M. & V. Vetvicka. 2008. Beta-glucans, history, and the present: immunomodulatory aspects and mechanisms of action. J. Immunot. 5: 47-57.
26. Falch, B.H. et al. 2000. The cytokine stimulating activity of (1 → 3)-beta-D-glucans is dependent on the triple helix conformation. Carbohyd. Res. 329: 587-596.
27. Pang, Z.C. et al. 2005. Structure of ss-glucan oligomer from laminarin and its effect on human monocytes to inhibit the proliferation ofU937 cells. Biosci.Biotechnol. Biochem. 69: 553-558.
28. Nisini, R. et al. 2007. Beta-Glucan of Candida albicans cell wall causes the subversion of human monocyte differentiation into dendritic cells. J. Leukoc. Biol. 82: 1136-1142.
29. Bohn, J.A. & J.N. BeMiller. 1995. (1→ 3)-beta-Dglucans as biological response modifiers: a review of structure-functional activity relationships. Carbohyd. Polym. 28: 3-14.
30. Omarsdottir, S., E.S. Olafsdottir & J. Freysdottir. 2006. Immunomodulating effects of lichen-derived polysaccharides on monocyte-derived dendritic cells. Int. Immunopharmacol. 6: 1642-1650.
31. Jones, G.H. & C.E. Ballou. 1969. Studies on the structure of Yeast Mannan. II. Mode of action of the arthobacter agr-mannosidase on yeast mannan. J. Biol. Chem. 244: 1052-1059.
32. Cambi, A. et al. 2008. Dendritic cell interaction with Candida albicans critically depends on N-linked mannan. J. Biol. Chem. 283: 20590-20599.
33. Liu, C. et al. 2006. Macrophage activation by polysaccharide biological responsemodifier isolated fromAloe vera L. var. chinensis (Haw.) Berg. Int. Immunopharmacol. 6: 1634-1641.
34. Qiu, Z.H. et al. 2000. Modified Aloe barbadensis polysaccharide with immunoregulatory activity. Planta Medica 66: 152-156.
35. Yu, Z. et al. 2009. Effect of Aloe vera polysaccharides on immunity and antioxidant activities in oral ulcer animal models. Carbohyd. Polym. 75: 307-311.
36. Im, S.A. et al. 2005. Identification of optimal molecular size of modified Aloe polysaccharides with maximum immunomodulatory activity. Int. Immunopharmacol. 5: 271-279.
37. Omarsdottir, S. et al. 2005. Effects of lichen heteroglycans on proliferation and IL-10 secretion by rat spleen cells and IL-10 and TNF-alpha secretion by rat peritoneal macrophages in vitro. Phytomedicine 12: 461-467.
38. Currier N.L., D. Lejtenyi & S.C. Miller 2003. Effect over time of in-vivo administration of the polysaccharide arabinogalactan on immune and hemopoietic cell lineages in murine spleen and bone marrow. Phytomedicine 10: 145-153.
39. Kelly, G.S. 1999. Larch arabinogalactan: clinical relevance of a novel immune-enhancing polysaccharide. Altern. Med. Rev. 4: 96-103.
40. Brecker, L. et al. 2005. Structural and immunological properties of arabinogalactan polysaccharides from pollen of timothy grass (Phleum pratense L.). Carbohydr. Res. 340: 657-663.
41. Capek, P. & V. Hribalova. 2004.Water-soluble polysaccharides from Salvia officinalis L. possessing immunomodulatory activity. Phytochemistry 65: 1983-1992.
42. Nergard, C.S. et al. 2006. Structures and structureactivity relationships of three mitogenic and complement fixing pectic arabinogalactans from the Malian antiulcer plants Cochlospermum tinctorium A. Rich and Vernonia kotschyana Sch Bip. ex Walp. Biomacromolecules 7: 71-79.
43. Inngjerdingen, M. et al. 2008. Pectic polysaccharides from Biophytum petersianum Klotzsch, and their activation of macrophages and dendritic cells. Glycobiology 18: 1074-1084.
44. Banchereau, J. & R.M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392: 245-252.
45. Taylor, P.R. et al. 2005. Macrophage receptors and immune recognition. Annu. Rev. Immunol 23: 901-944.
46. Gamal-Eldeen, A.M. et al. 2007. Chemically-modified polysaccharide extract derived from Leucaena leucocephala altersRaw264.7murinemacrophage functions. Int. Immunopharmacol. 7: 871-878.
47. Estrada, A. et al. 1997. Immunomodulatory activities of oat beta-glucan in vitro and in vivo. Microbiol. Immunol. 41: 991-998.
48. Estrada, A. et al. 1998. Effect of endotoxin on cytokine production and cell dynamics in mice. Immunopharmacol. Immunotoxicol. 20: 217-231.
49. Schepetkin, I.A. et al. 2005.Macrophage immunomodulatory activity of polysaccharides isolated from Juniperus scopolorum. Int. Immunopharmacol. 5: 1783-1799.
50. Nair, P.K.R. et al. 2006.Mechanism ofmacrophage activation by (1,4)-alpha-D-glucan isolated fromTinospora cordifolia. Int. Immunopharmacol. 6: 1815-1824.
51. Zhu, J. et al. 2007. Lycium barbarum polysaccharides regulate phenotypic and functional maturation of murine dendritic cells. Cell Biol. Int. 31: 615-619.
52. Leiro, J.M. et al. 2007. Immunomodulating activities of acidic sulphated polysaccharides obtained from the seaweed Ulva rigida C. Agardh. Int. Immunopharmacol. 7: 879-888.
53. Kim, M.H. & H.G. Joo. 2008. Immunostimulatory effects of fucoidan on bone marrow-derived dendritic cells. Immunol. Lett. 115: 138-143.
54. Luo, X. et al. 2008. Characterisation and immunostimulatory activity of an [alpha]-(1→ 6)-d-glucan from the cultured Armillariella tabescens mycelia. Food Chem. 111: 357-363.
55. Li, B. et al. 2007. Yeast glucan particles activate murine resident macrophages to secrete proinflammatory cytokines via MyD88- and Syk kinase-dependent pathways. Clin. Immunol. 124: 170-181.
56. Villena, S.N. et al. 2008.Capsularpolysaccharides galactoxylomannan and glucuronoxylomannan from Cryptococcus neoformans induce macrophage apoptosis mediated by Fas ligand. Cell.Microbiol. 10: 1274-1285.
57. Adachi, Y. et al. 1994. Enhancement of cytokine production by macrophages stimulated with (1-]3)- beta-D-glucan, Grifolan (Grn), isolated from Grifola- Frondosa. Biol. Pharm. Bull. 17: 1554-1560.
58. Ishibashi, K. et al. 2001. Relationship between solubility of grifolan, a fungal 1,3-beta-D-glucan, and production of tumor necrosis factor bymacrophages in vitro. Biosci. Biotechnol. Biochem. 65: 1993-2000.
59. Okazaki, M. et al. 1995. Structure-activity relationship of (1-]3)-beta-D-glucans in the induction of cytokine production from macrophages, in-vitro. Biol. Pharm. Bull. 18: 1320-1327.
60. Chan, W.K. et al. 2007. Response of human dendritic cells to different immunomodulatory polysaccharides derived from mushroom and barley. Int. Immunol. 19: 891-899.
61. Gerosa, F. et al. 2008. Differential regulation of interleukin 12 and interleukin 23 production in human dendritic cells. J. Exp. Med. 205: 1447-1461.
62. Dillon, S. et al. 2006. Yeast zymosan, a stimulus for TLR2 and dectin-1, induces regulatory antigenpresenting cells and immunological tolerance. J. Clin. Invest. 116: 916-928.
63. Rogers, N.C. et al. 2005. Syk-dependent cytokine induction by dectin-1 reveals a novel pattern recognition pathway for C type lectins. Immunity 22: 507-517.
64. Pugh, N.D. et al. 2008. The majority of in vitro macrophage activation exhibited by extracts of some immune enhancing botanicals is due to bacterial lipoproteins and lipopolysaccharides. Int. Immunopharmacol. 8: 1023-1032.
65. Dennehy, K.M. & G.D. Brown. 2007. The role of the beta-glucan receptor dectin-1 in control of fungal infection. J. Leukoc. Biol. 82: 253-258.
66. Hong, F. et al. 2003. Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Res. 63: 9023-9031.
67. Rice, P.J. et al. 2005. Oral delivery and gastrointestinal absorption of soluble glucans stimulate increased resistance to infectious challenge. J. Pharmacol. Exp. Ther. 314: 1079-1086.
68. Tsukagoshi, S. et al. 1984. Krestin (PSK). Cancer Treat. Rev. 11: 131-155.
69. Rice, P.J. et al. 2004. Pharmacokinetics of fungal (1-3)- beta-D-glucans following intravenous administration in rats. Int. Immunopharmacol. 4: 1209-1215.
70. Vetvicka, V. et al. 2007. Orally administered marine (1 → 3)-[beta]-d-glucan Phycarine stimulates both humoral and cellular immunity. Int. J. Biol. Macromol. 40: 291-298.
71. Hoshi, H. et al. 2008.Absorption and tissue distribution of an immunomodulatory alpha-D-glucan after oral administration of Tricholoma matsutake. J. Agric. Food Chem. 56: 7715-7720.
72. Sakurai, M.H. et al. 1996. Detection and tissue distribution of anti-ulcer pectic polysaccharides from Bupleurum falcatum by polyclonal antibody. Planta Med. 62: 341-346.
73. Sakurai, M.H. et al. 1999. B-cell proliferation activity of pectic polysaccharide from a medicinal herb, the roots of Bupleurum falcatum L. and its structural requirement. Immunology 97: 540-547.
74. Mueller, A. et al. 2000. The influence of glucan polymer structure and solution conformation on binding to (1→ 3)-{beta}-D-glucan receptors in a human monocytelike cell line. Glycobiology 10: 339-346.
75. Hashimoto, K., I. Suzuki & T. Yadomae. 1991. Oral administration of SSG, a beta-glucan obtains from Sclerotinia-sclerotiorum, affects the function of Peyer's patch cells. Int. J. Immunopharmacol. 13: 437-442.
76. Sandvik, A. et al. 2007. Oral and systemic administration of beta-glucan protects against lipopolysaccharideinduced shock and organ injury in rats. Clin. Exp. Immunol. 148: 168-177.
77. Rescigno, M. et al. 2001. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat. Immunol. 2: 361-367.
78. Macpherson, A.J. & K. Smith. 2006. Mesenteric lymph nodes at the center of immune anatomy. J. Exp. Med. 203: 497-500.
79. Hong, F. et al. 2004. Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumormonoclonal antibodies inmurine tumor models. J. Immunol. 173: 797-806.
80. Liang, J. et al. 1998. Enhanced clearance of a multiple antibiotic resistant Staphylococcus aureus in rats treated with PGG-glucan is associated with increased leukocyte counts and increased neutrophil oxidative burst activity. Int J. Immunopharmacol. 20: 595-614.
81. Kournikakis, B. et al. 2003. Anthrax-protective effects of yeast beta 1,3 glucans. Med. Gen. Med. 5: 1.
82. Dritz, S.S. et al. 1995. Influence of dietary beta-glucan on groth-performance, non-specific immunity, and resistance to streptococcus-suis infectin in wealing pigs. J. Anim. Sci. 73: 3341-3350.
83. Ahn, J.Y. et al. 2006. Protection of Staphylococcus aureus-infected septic mice by suppression of early acute inflammation and enhanced antimicrobial activity by ginsan. FEMS. Immunol. Med. Microbiol. 46: 187-197.
84. Bernardshaw, S., E. Johnson & G. Hetland. 2005. An extract of the mushroom Agaricus blazei Murill administered orally protects against systemic Streptococcus pneumoniae infection in mice. Scand. J. Immunol. 62: 393-398.
85. Hetland, G. et al. 2000. Protective effect of beta-glucan against systemic Streptococcus pneumoniae infection in mice. FEMS. Immunol. Med. Microbiol. 27: 111-116.
86. Yun, C.H. et al. 1997. Beta-(1→ 3, 1→ 4) oat glucan enhances resistance to Eimeria vermiformis infection in immunosuppressed mice. Int. J. Parasitol. 27: 329-337.
87. Yun, C.H. et al. 1998. Immunomodulatory effects of oat beta-glucan administered intragastrically or parenterally on mice infected with Eimeria vermiformis. Microbiol. Immunol. 42: 457-465.
88. Bedirli, A. et al. 2007. Beta-glucan attenuates inflammatory cytokine release and prevents acute lung injury in an experimental model of sepsis. Shock 27: 397-401.
89. Behrens, E.M. et al. 2007. Complement receptor 3 ligation of dendritic cells suppresses their stimulatory capacity. J. Immunol. 178: 6268-6279.
90. de Sousa, A.P.A. et al. 2007. In vivo growth-inhibition of Sarcoma 180 tumor by alginates frombrown seaweed Sargassum vulgare. Carbohyd. Polym. 69: 7-13.
91. Demir, G. et al. 2007. Beta glucan induces proliferation and activation of monocytes in peripheral blood of patients with advanced breast cancer. Int. Immunopharmacol. 7: 113-116.
92. Gan, L. et al. 2004. Immunomodulation and antitumor activity by a polysaccharide-protein complex from Lycium barbarum. Int. Immunopharmacol. 4: 563-569.
93. Hu, X.K. et al. 2006. Preparation and in vivo antitumor activity of kappa-carrageenan oligosaccharides. Pharm. Biol. 44: 646-650.
94. Kimura, Y. et al. 2006. Antitumor and antimetastatic activity of a novel water-soluble low molecular weight beta-1,3-D-glucan (branch beta-1,6) isolated fromAureobasidium pullulans 1A1 strain black yeast. Anticancer Res. 26: 4131-4141.
95. Li, B. et al. 2007. Combined yeast beta-glucan and antitumor monoclonal antibody therapy requires C5amediated neutrophil chemotaxis via regulation of decay-accelerating factor CD55. Cancer Res. 67: 7421-7430.
96. Yoon, T.J. et al. 2008. Anti-tumor metastatic activity of [beta]-glucan purified from mutated Saccharomyces cerevisiae. Int. Immunopharmacol. 8: 36-42.
97. Zhou, G. et al. 2004. In vivo antitumor and immunomodulation activities of different molecular weight lambda-carrageenans from Chondrus ocellatus. Pharmacol. Res. 50: 47-53.
98. Yan, J. et al. 1999. Beta-glucan, a "Specific" biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18). J. Immunol. 163: 3045-3052.
99. Cheung, N.K. & S. Modak 2002. Oral (1→ 3),(1→ 4)- beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Clin. Cancer Res. 8: 1217-1223.
100. Cheung, N.K. et al. 2002. Orally administered betaglucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunol. Immunother. 51: 557-564.
101. Xia, Y. et al. 1999. The beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. J. Immunol. 162: 2281-2290.
102. Modak, S. et al. 2005. Rituximab therapy of lymphoma is enhanced by orally administered (→13),(1→ 4)-Dbeta- glucan. Leuk. Res. 29: 679-683.
103. Hida, S. et al. 2005. Effect of Candida albicans cell wall glucan as adjuvant for induction of autoimmune arthritis in mice. J. Autoimmun. 25: 93-101.
104. Yoshioka, S. et al. 1998. Immunotoxicity of soluble betaglucans induced by indomethacin treatment. FEMS. Immunol. Med. Microbiol. 21: 171-179.
105. Billar,T. R. 1995.Nitric oxide, novel biology and clinical relevance. Ann. Surg. 221: 339-349.